Sector Update: Shares Flat Pre-Market; TG Therapeutics Sinks 5% on Preliminary Clinical Results
Top Healthcare stocks:
Healthcare shares were fairly flat in pre-market trade on Friday.
In healthcare stocks news, Aratana Therapeutics ( PETX ) late Thursday announced an agreement to gain exclusive rights to sell and develop a treatment for pain and inflammation of osteoarthritis in dogs based on Vet-Stem's allogeneic stem cell therapy technology. If approved, Vet-Stem's technology will be the first FDA-regulated, "off the shelf" regenerative cell therapy for the treatment of osteoarthritis in dogs.
And, TG Therapeutics, Inc. ( TGTX ), a clinical-stage biopharmaceutical company, shares were down about 5% after it announced preliminary clinical results from its ongoing Phase 2 study of TG-1101, the company's novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib,
The oral BTK inhibitor from Pharmacyclics/Janssen. Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association meeting being held in Milan, Italy.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.